Analysts Set PolyPid Ltd. (NASDAQ:PYPD) PT at $11.67

Shares of PolyPid Ltd. (NASDAQ:PYPD) have been given an average recommendation of “Moderate Buy” by the five research firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $11.3333.

A number of equities research analysts have recently weighed in on the company. Craig Hallum set a $12.00 target price on PolyPid in a research note on Wednesday. Weiss Ratings raised PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Finally, HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of PolyPid in a research report on Tuesday.

Key Stories Impacting PolyPid

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on PolyPid and maintained a $13 price target, signaling continued confidence in the stock’s longer-term potential. The firm also slightly raised its Q2 2026 EPS estimate and Q4 2026 EPS estimate, which may help support sentiment. Article Title
• Neutral Sentiment: HC Wainwright made several forecast adjustments for future years, with some estimates improving and others declining. The changes suggest analysts still see meaningful uncertainty in PolyPid’s earnings path, but not a major shift in the overall investment thesis.
• Negative Sentiment: Short interest in PolyPid (PYPD) rose sharply in July to 283,206 shares, up 235.2% from late June, with about 2.0% of shares sold short. Rising short interest can indicate growing skepticism among traders and may weigh on the stock. Article Title
• Negative Sentiment: HC Wainwright cut its FY2027, FY2028, FY2029, and FY2030 EPS estimates for PolyPid, including a sizeable reduction to FY2030 expectations. Lower long-term earnings forecasts can pressure valuation expectations, even though the firm kept its bullish rating. Article Title

PolyPid Stock Down 8.0%

PolyPid stock opened at $3.90 on Wednesday. The company has a market capitalization of $74.42 million, a PE ratio of -2.04 and a beta of 1.40. The firm has a fifty day simple moving average of $4.84 and a two-hundred day simple moving average of $4.58. PolyPid has a twelve month low of $3.06 and a twelve month high of $5.73.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.12. As a group, equities analysts expect that PolyPid will post -0.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PolyPid

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PYPD. AIGH Capital Management LLC grew its holdings in PolyPid by 26.1% in the 4th quarter. AIGH Capital Management LLC now owns 1,342,972 shares of the company’s stock worth $5,828,000 after acquiring an additional 277,844 shares during the last quarter. Jane Street Group LLC bought a new position in shares of PolyPid during the fourth quarter valued at about $66,000. ADAR1 Capital Management LLC bought a new position in shares of PolyPid during the fourth quarter valued at about $451,000. XTX Topco Ltd raised its stake in shares of PolyPid by 50.0% during the fourth quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after acquiring an additional 10,888 shares during the last quarter. Finally, HighTower Advisors LLC purchased a new stake in shares of PolyPid during the fourth quarter worth about $44,000. 26.47% of the stock is currently owned by institutional investors.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.